Bloomberg (12/12, Fourcade) reports, “Another party drug is showing signs of going legit as” psilocybin, the active ingredient in “magic mushrooms, cleared the first hurdle of tests required to become a treatment for depression.”    Newsweek (12/12, Gander) reports that in “what was the largest controlled study of psilocybin,” UK investigators “tested the drug on 89 volunteers aged around 35.” They concluded that “psilocybin caused no serious problems, including to participants’ cognition and emotional functions.” The findings were presented at the annual meeting of the American College of Neuropsychopharmacology. (SOURCE: APA Headlines)